RxDoctor Payments Data

Ryan Chartrand, DO

Urology · Madison Heights, MINPI 1720341894

Payments from drug & device makers

$9,628in general payments, 2019–2025

Across 370 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$3K
  • AbbVie$920
  • Astellas Pharma US Inc$594
  • Teleflex LLC$507
  • Merck$398
  • Urogen Pharma, Inc.$356
  • plus $4K from 40 others

What the payments were for

  • Travel & lodging$2,05521%
  • Food & beverage$7,38177%
  • Education$1922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,628 in reported general payments places this provider in the 75th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$315,687
Medicare patients
649
Services billed
4,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide25$342,936
OrgovyxRelugolix16$39,495
MyrbetriqMirabegron57$38,395
GemtesaVibegron34$21,779
Mirabegron ErMirabegron22$13,753
Tamsulosin Hcl416$8,833
Finasteride268$6,682
Oxybutynin Chloride ErOxybutynin Chloride126$4,334
Trospium Chloride27$3,130
NitrofurantoinNitrofurantoin Macrocrystal40$2,207
Cephalexin65$1,511
Solifenacin Succinate26$915
Potassium Citrate ErPotassium Citrate16$518
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$365
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim87$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$594$381,33182 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$177$61,27450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 400 urology providers in Michigan.

Other urology in Madison Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →